



US006113629A

United States Patent [19]

[11] **Patent Number:** **6,113,629**

Ken

[45] **Date of Patent:** **Sep. 5, 2000**

[54] **HYDROGEL FOR THE THERAPEUTIC TREATMENT OF ANEURYSMS**

5,662,609 9/1997 Slepian .
5,665,063 9/1997 Roth et al. .
5,667,767 9/1997 Greff et al. 424/9.411
5,674,287 10/1997 Slepian et al. .

[75] Inventor: **Christopher G. M. Ken**, San Mateo, Calif.

FOREIGN PATENT DOCUMENTS

[73] Assignee: **Micrus Corporation**, Mountain View, Calif.

0 547 530 A1 6/1993 European Pat. Off. .
WO 98/55174 11/1997 WIPO .
WO 97/45131 12/1997 WIPO .
WO 97/40849 12/1998 WIPO .
WO 99/29260 6/1999 WIPO .

[21] Appl. No.: **09/071,250**

[22] Filed: **May 1, 1998**

OTHER PUBLICATIONS

[51] **Int. Cl.**⁷ **A61F 2/06**

Copy of the International Search Report Relating to PCT/US99/09492 Dated Aug. 17, 1999.

[52] **U.S. Cl.** **623/1.1**; 604/49; 604/96; 606/213

Patent Abstracts of Japan Publication No. 05017369, Publication Date Jan. 26, 1993.

[58] **Field of Search** 623/1, 11, 12; 604/96, 100, 49, 53; 606/108, 213; 424/426; 514/21

Primary Examiner—Mickey Yu
Assistant Examiner—Choon P. Koh
Attorney, Agent, or Firm—Fulwider Patton Lee & Utecht, LLP

[56] **References Cited**

U.S. PATENT DOCUMENTS

[57] **ABSTRACT**

2,726,982	12/1955	Ochs et al. .	
4,565,784	1/1986	Franzblau et al. .	
4,795,741	1/1989	Leshchiner et al.	514/21
4,878,907	11/1989	Okada et al. .	
5,213,580	5/1993	Slepian et al. .	
5,213,720	5/1993	Civerchia .	
5,258,042	11/1993	Mehta .	
5,328,471	7/1994	Slepian .	
5,410,016	4/1995	Hubbell et al. .	
5,514,379	5/1996	Weissleder et al.	424/426
5,522,888	6/1996	Civerchia .	
5,575,815	11/1996	Slepian et al. .	
5,580,568	12/1996	Greff et al. .	
5,604,200	2/1997	Taylor-McCord .	
5,624,685	4/1997	Takahashi et al.	424/488
5,626,863	5/1997	Hubbell et al. .	
5,634,936	6/1997	Linden et al. .	
5,634,946	6/1997	Slepian .	

The hydrogel for the treatment of aneurysms acts as a carrier for both a radiopaque agent allowing the hydrogel to be visualized under fluoroscopy and a therapeutic agent such as one or more human growth factors. The hydrogel is delivered through a catheter into the aneurysm, where the hydrogel becomes more viscous upon reaching body temperature, or upon exposure to bodily fluids, to block blood flow into the aneurysm. In addition to stopping blood flow into the aneurysm, the delivery of human growth factors to the aneurysm site promotes the growth of a cellular layer across the neck of the aneurysm. The hydrogel may be of a type that dissolves over time or one which remains as a permanent occlusive agent within the aneurysm.

10 Claims, No Drawings